This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Wyeth, Elan Halt Alzheimer Drug Trial

Wyeth (WYE) and Elan (ELN) suspended a clinical trial involving their experimental Alzheimer vaccine ACC-001 after a single patient was hospitalized due to a skin lesion.

ACC-001 is a vaccine designed to prime the body's immune system to create antibodies against beta amyloid, the toxic protein that forms plaques in the brain believed to play a key role in Alzheimer disease.

Wyeth and Elan are developing ACC-001 as a second-generation version of an older Alzheimer vaccine, AN1792. The latter vaccine's development was stopped in 2001 after some patients were hospitalized due to swelling in the brain.

According to Elan spokesman Jonathan Birt, one patient dosed with ACC-001 in a phase II trial was hospitalized with what the patient's physician described as a "skin lesion, possibly vasculitis." The patient was treated successfully and has since been discharged from the hospital.

Vasculitis is an inflammation of blood vessels that can be caused by an immune, or allergic, reaction. The severity of vasculitis can vary widely, but Birt had no more information about the ACC-001 patient.

A later biopsy, however, did not confirm vasculitis, according to a Wyeth spokesperson.

Elan and Wyeth have informed regulators both in the U.S. and Europe about the hospitalization, which led to the suspension of the ACC-001 clinical trial. The study has not been permanently halted, Birt says.

A notice of the ACC-001 study suspension was posted on the Web site.

The negative safety signal detected with ACC-001 has not affected the ongoing clinical trials of bapineuzumab, the other major Alzheimer drug being developed by Elan and Wyeth, Birt says.

Thursday's news comes one day after Elan shares rose sharply after the company and partner Biogen Idec (BIIB) reported a stronger-than-expected increase in the number of patients treated with their multiple sclerosis drug Tysabri.

Elan shares were down 4.1% at $23.31 in recent trading, while Wyeth shares were losing 1.5% to $43.57.

Adam Feuerstein writes regularly for In keeping with TSC's editorial policy, he doesn't own or short individual stocks, although he owns stock in He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,053.71 +23.50 0.13%
S&P 500 2,088.77 +6.89 0.33%
NASDAQ 4,806.8590 +33.3870 0.70%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs